Long-term medical costs and life expectancy of acute myeloid leukemia: A probabilistic decision model

Value in Health

Volumn 17, Issue 2, 2014, Pages 205-214

  Wang, Han I ^a   Aas, Eline ^b   Howell, Debra ^a   Roman, Eve ^a   Patmore, Russell ^c   Jack, Andrew ^d   Smith, Alexandra ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF OSLO   (Norway)

^c CASTLE HILL HOSPITAL   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

acute myeloid lymphoma; costs; decision analytic model; life expectancy

Indexed keywords

CLOFARABINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; DECISION TREE; EXTERNAL VALIDITY; FACE VALIDITY; HEALTH CARE COST; HUMAN; INTERNAL VALIDITY; LEUKEMIA REMISSION; LIFE EXPECTANCY; LOW DRUG DOSE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION; PRIORITY JOURNAL; PROBABILISTIC DECISION MODEL; PROBABILITY; STATISTICAL MODEL; SURVIVAL RATE; TIME; TREATMENT RESPONSE; UNCERTAINTY; UNITED KINGDOM;

ACUTE MYELOID LYMPHOMA; COSTS; DECISION ANALYTIC MODEL; LIFE EXPECTANCY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DECISION TREES; GREAT BRITAIN; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIFE EXPECTANCY; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; REGISTRIES; SURVIVAL; TIME FACTORS; YOUNG ADULT;

EID: 84896368579     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.12.007     Document Type: Article

References (35)

1. A. Burnett, M. Wetzler, and B. Löwenberg Therapeutic advances in acute myeloid leukemia J Clin Oncol 29 2011 487 494
2. D.A. Breems, W.L.J. Van Putten, and P.C. Huijgens et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse J Clin Oncol 23 2005 1969 1978 (Pubitemid 46211376)
3. C. Ganzel, and J.M. Rowe Prognostic factors in adult acute leukemia Hematol/Oncol Clin North Am 25 2011 1163 1187
4. D.L. Uhlman, C.D. Bloomfield, D.D. Hurd, and B.A. Peterson Prognostic factors at relapse for adults with acute myeloid leukemia Am J Hematol 33 1990 110 116 (Pubitemid 20040087)
5. H.M. Kantarjian, M.J. Keating, and R.S. Walters et al. The characteristics and outcome of patients with late relapse acute myelogenous leukemia J Clin Oncol 6 1988 232 238 (Pubitemid 18065927)
6. B.C. Medeiros, M.D. Minden, and A.C. Schuh et al. Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years) Leuk Lymphoma 48 2007 65 71
7. F. Giles, S. Verstovsek, and G. Garcia-Manero et al. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse Br J Haematol 134 2006 58 60 (Pubitemid 43830028)
8. E.H. Estey, Y. Shen, and P.F. Thall Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB Blood 95 2000 72 77 (Pubitemid 30017227)
9. W. Kern, T. Haferlach, and C. Schoch et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial Blood 101 2003 64 70 (Pubitemid 36025888)
10. F.R. Appelbaum, H. Gundacker, and D.R. Head et al. Age and acute myeloid leukemia Blood 107 2006 3481 3485
11. G. Juliusson, P. Antunovic, and A. Derolf et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Blood 113 2009 4179 4187
12. E. Berman, C. Little, and B. Teschendorf et al. Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy Cancer 95 2002 1064 1070 (Pubitemid 34925358)
13. V. Nerich, B. Lioure, and M. Rave et al. Induction-related cost of patients with acute myeloid leukaemia in France Int J Clin Pharm 33 2011 191 199
14. P.J. Lobo, R.L. Powles, A. Hanrahan, and D.K. Reynold Acute myeloblastic leukaemia-a model for assessing value for money for new treatment programmes BMJ 302 1991 323 326
15. C.A. Uyl-de Groot, J. Gelderblom-den Hartog, and P.C. Huijgens et al. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands J Hematother Stem Cell Res 10 2001 187 192 (Pubitemid 32233704)
16. G.R. Tennvall, U. Persson, and B. Nilsson The economic costs of acute myeloid leukemia in Sweden Int J Technol Assess Health Care 10 1994 683 694 (Pubitemid 24371302)
17. A.M. Stalfelt, and H. Brodin Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades J Intern Med 236 1994 401 409 (Pubitemid 24323200)
18. A.M. Stalfelt, H. Brodin, and B. Wadman Cost analysis of different phases of acute myeloid leukaemia Leuk Res 18 1994 783 790 (Pubitemid 24302106)
19. K. Lang, C.C. Earle, and T. Foster et al. Trends in the treatment of acute myeloid leukaemia in the elderly Drugs Aging 22 2005 943 955 (Pubitemid 41746575)
20. J. Menzin, K. Lang, and C.C. Earle et al. The outcomes and costs of acute myeloid leukemia among the elderly Arch Intern Med 162 2002 1597 1603 (Pubitemid 34773427)
21. A. Smith, E. Roman, and D. Howell et al. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research Br J Haematol 148 2010 739 753
22. A.K. Burnett, N.H. Russell, and R.K. Hills et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia J Clin Oncol 30 2012 3924 3931
23. A.K. Burnett, R.K. Hills, and D. Milligan et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial J Clin Oncol 29 2011 369 377
24. K. Wheatley, C.L. Brookes, and A.J. Howman et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials Br J Haematol 145 2009 598 605
25. A. Briggs, M. Sculpher, and K. Claxton Decision Modelling for Health Economic Evaluation 2006 Oxford, UK: Oxford University Press
26. G. Gianfaldoni, F. Mannelli, and M. Baccini et al. Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study Br J Haematol 134 2006 54 57 (Pubitemid 43830027)
27. K. Hussein, B. Jahagirdar, and P. Gupta et al. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia Am J Hematol 83 2008 446 450 (Pubitemid 351742790)
28. D.W. Milligan, D. Grimwade, and J.O. Cullis et al. Guidelines on the management of acute myeloid leukaemia in adults Br J Haematol 135 2006 450 474 (Pubitemid 44596187)
29. Haematology Clinical Network Group. Clinical Guidelines for the Management of Acute Myeloid Leukaemia (AML). MCCN AML Guidelines. Clinical Guidelines for the Management of Acute Myeloid Leukaemia (AML). Available from: http://www.mccn.nhs.uk/userfiles/documents/ Guidelines%20for%20the%20management%20of%20AML%20February%202011%281%29.pdf. [Accessed January 12, 2013].
30. F.A. Sonnenberg, and J.R. Beck Markov models in medical decision making: a practical guide Med Decis Making 13 1993 322 338 (Pubitemid 24013155)
31. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2008. 2012. Available from: http://www.nice.org.uk/ media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. [Accessed January 12, 2014].
32. D.M. Eddy, W. Hollingworth, and J.J. Caro et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7 Value Health 15 2012 843 850
33. J.F. San Miguel, M.B. Vidriales, and C. López-Berges et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification Blood 98 2001 1746 1751
34. F. Buccisano, L. Maurillo, and M.I. Del Principe et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia Blood 119 2012 332 341
35. Department of Health. Programme Budgeting PCT Benchmarking Tool. Available from: http://www.networks.nhs.uk/nhs-networks/health-investment- network/news/2011-12-programme-budgeting-data-now-available. [Accessed January 19, 2012].